Skip to main content
Premium Trial:

Request an Annual Quote

Navigenics Cuts Price of Screening Service 60 Percent

NEW YORK (GenomeWeb News) – Consumer genomics firm Navigenics has cut the price of its comprehensive genetic screening service by 60 percent, from $2,500 to $999, the firm announced on its blog, The Navigator.

A thousand dollars buys customers a year subscription to Navigenics' Health Compass testing services, which includes genetic risk data for 28 diseases and conditions; an hour-long session with a genetic counselor; and updates to risk scores as new gene associations and diseases are added to the service.

Navigenics launched Health Compass in 2007. The company conducts its genetic risk scans using Affymetrix arrays, and earlier this year it took over ownership of Affy's CLIA lab.

Also earlier this year, Navigenics launched a pared down version of its service, Annual Insight, that costs $499 and provides individuals with information about their genetic predisposition for 10 common health conditions, including breast, colon, and prostate cancer, celiac disease, Crohn's disease, type 2 diabetes, glaucoma, heart attack, macular degeneration, and osteoarthritis. The company markets this version of its service to doctors, aiming to drive the integration of genomic information into people's yearly medical checkups.

Navigenics is not the only the firm to drop the price of its DTC genomics service offering. Last year, one of its competitors, 23andMe, lowered the cost of its service from $999 to $399, citing technological advancements in the Illumina platform.

Further competitive pressure has come from the launch this week of Pathway Genomics, a San Diego-based DTC genetic testing firm that is offering genotyping and analysis for disease risk and heredity for under $250.

A more detailed version of this article is available on GenomeWeb Daily News sister publication Pharmacogenomics Reporter.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.